Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT02644967 | A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma | completed | Phase 2 | 53 | Idera Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 3, 2022 | clinicaltrials |
| NCT02130466 | A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) | completed | Phase 1 / Phase 2 | 184 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 1, 2022 | clinicaltrials |
| NCT00068172 | Study of PI-88 in Patients With Advanced Melanoma | completed | Phase 1 / Phase 2 | 88 | Cellxpert Biotechnology Corp.INDUSTRY | 1 | Jun 27, 2022 | clinicaltrials |
| NCT00073892 | PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 44 | Cellxpert Biotechnology Corp.INDUSTRY | 2 | Jun 27, 2022 | clinicaltrials |
| NCT00130442 | Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma | completed | Phase 2 | 134 | Cellxpert Biotechnology Corp.INDUSTRY | 2 | Jun 23, 2022 | clinicaltrials |
| NCT00602576 | Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma | completed | Phase 2 | 169 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT01134250 | Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients | completed | Phase 1 / Phase 2 | 48 | Philogen S.p.A.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT00084656 | Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma | completed | Phase 2 | 77 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 14, 2022 | clinicaltrials |
| NCT01127451 | Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma | completed | Phase 2 | 75 | Eisai Inc.INDUSTRY | 1 | Apr 13, 2022 | clinicaltrials |
| NCT02111850 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive | completed | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2022 | clinicaltrials |
| NCT02626962 | Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma(GEM1402) | completed | Phase 2 | 52 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT01927419 | Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma(CheckMate 069) | completed | Phase 2 | 142 | Bristol-Myers SquibbINDUSTRY | 2 | Mar 18, 2022 | clinicaltrials |
| NCT01959633 | Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation(VEMUPLINT) | completed | Phase 1 / Phase 2 | 11 | Fondazione Melanoma OnlusOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT04062032 | Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma | completed | Phase 2 | 41 | University of UtahOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT04066725 | Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma | completed | Phase 2 | 95 | University of UtahOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT01827111 | Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma | completed | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT03278665 | 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy(SENSITIZE) | completed | Phase 1 / Phase 2 | 40 | 4SC AGINDUSTRY | 2 | Feb 4, 2022 | clinicaltrials |
| NCT02083354 | Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma | completed | Phase 2 | 77 | Novartis PharmaceuticalsINDUSTRY | 5 | Feb 1, 2022 | clinicaltrials |
| NCT02225366 | Intratumoral Injections of LL37 for Melanoma | completed | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT00910650 | Study of Gene Modified Immune Cells in Patients With Advanced Melanoma(F5) | completed | Phase 2 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 6, 2021 | clinicaltrials |
| NCT02366195 | Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma(TVEC-325) | completed | Phase 2 | 112 | AmgenINDUSTRY | 13 | Nov 30, 2021 | clinicaltrials |
| NCT00591734 | RAD001 Plus Bevacizumab in Metastatic Melanoma | completed | Phase 2 | 57 | SCRI Development Innovations, LLCOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT02009397 | A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients | completed | Phase 1 / Phase 2 | 27 | University of LouisvilleOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT02129075 | A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 16, 2021 | clinicaltrials |
| NCT02320058 | An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself(CheckMate204) | completed | Phase 2 | 119 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 5, 2021 | clinicaltrials |
| NCT02574377 | myDC/pDC in Stage III Melanoma Patients | completed | Phase 1 / Phase 2 | 30 | Radboud University Medical CenterOTHER | 1 | Sep 20, 2021 | clinicaltrials |
| NCT01335009 | Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma | completed | Phase 2 | 76 | Eisai Inc.INDUSTRY | 4 | Sep 1, 2021 | clinicaltrials |
| NCT00960752 | Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist | completed | Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT01783938 | Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) | completed | Phase 2 | 138 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 13, 2021 | clinicaltrials |
| NCT02071940 | PLX3397 KIT in Acral aNd mucOsal Melanoma(PIANO) | completed | Phase 2 | 7 | The Christie NHS Foundation TrustOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT01497808 | RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA | completed | Phase 1 / Phase 2 | 22 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT02296112 | Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations | completed | Phase 2 | 9 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 28, 2021 | clinicaltrials |
| NCT00118274 | Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 170 | Craig L Slingluff, JrOTHER | 1 | Apr 20, 2021 | clinicaltrials |
| NCT00896480 | Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma | completed | Phase 2 | 24 | GlaxoSmithKlineINDUSTRY | 2 | Apr 8, 2021 | clinicaltrials |
| NCT01302496 | Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma(TriMix-Ipi) | completed | Phase 2 | 39 | Bart NeynsOTHER | 1 | Mar 29, 2021 | clinicaltrials |
| NCT01967823 | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2021 | clinicaltrials |
| NCT02085070 | MK-3475 in Melanoma and NSCLC Patients With Brain Metastases | completed | Phase 2 | 65 | Yale UniversityOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT00303251 | Safety of TKI258 in Advanced/Metastatic Melanoma Subjects | completed | Phase 1 / Phase 2 | 47 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 11, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT02902042 | Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma(IMMU-TARGET) | completed | Phase 1 / Phase 2 | 16 | Prof. Dr. med. Dirk SchadendorfOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT01321437 | Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma | completed | Phase 2 | 11 | University of California, IrvineOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT02493361 | Trial of pIL-12/MK-3475 in Metastatic Melanoma | completed | Phase 2 | 24 | University of California, San FranciscoOTHER | 1 | Jan 6, 2021 | clinicaltrials |
| NCT00304525 | A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma(CHIR-265-MEL01) | completed | Phase 1 / Phase 2 | 104 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 19, 2020 | clinicaltrials |
| NCT02308020 | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain | completed | Phase 2 | 162 | Eli Lilly and CompanyINDUSTRY | 9 | Dec 19, 2020 | clinicaltrials |
| NCT02423863 | In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®(Poly-ICLC) | completed | Phase 2 | 26 | Oncovir, Inc.INDUSTRY | 1 | Dec 17, 2020 | clinicaltrials |
| NCT00942162 | A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma(PREDICT) | completed | Phase 2 | 125 | GlaxoSmithKlineINDUSTRY | 8 | Dec 8, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 3, 2022source: clinicaltrials